Q3 2024 Earnings Summary
- Strong performance in Pharmacy and Consumer Wellness segment: CVS achieved a record-high retail pharmacy script share of 27.3%, up 70+ basis points year-over-year . This growth is attributed to improved service levels, with Net Promoter Score (NPS) levels up hundreds of basis points year-over-year, driving strong prescription growth .
- Strategic initiatives driving margin expansion in 2025: CVS expects margin expansion due to deliberate benefit design changes, exiting underperforming products, and an anticipated $800 million tailwind from improved Star ratings for 2025, with two-thirds of Medicare Advantage members in 4.5-star plans . These actions are aimed at improving profitability and driving margin growth into 2026 .
- Successful rollout of Cost Vantage program: CVS's Cost Vantage program, aimed at addressing reimbursement pressure and transforming pharmaceutical pricing, has over 50% of clients enrolled, with expectations to have 100% of the commercial book signed by the end of the year . This initiative is expected to bring stability to pricing strategies and improve service to members and clients .
- CVS anticipates Medicare Advantage membership disenrollment of 5% to 10% in 2025, due to benefit reductions and exiting underperforming counties, potentially impacting revenue and profitability.
- Unfavorable medical cost trends in the Health Care Benefits segment are expected to reach the highest levels, with these trends projected to persist through Q4 2024.
- Medical Loss Ratios (MLR) are expected to increase significantly, potentially reaching 95.5% in Q4 2024, indicating rising costs and pressure on margins.
| Metric | YoY Change | Reason |
|---|---|---|
Total Revenue | +6% | Strong performance in the Health Care Benefits and Pharmacy & Consumer Wellness segments drove top-line growth, offset by a decline in Health Services due to the loss of a large client and continued pharmacy pricing pressures. The acquisitions of Oak Street Health and Signify Health also contributed to revenue gains. |
Health Care Benefits | +26% | Membership growth in Medicare Advantage and Commercial lines, along with increased premiums and higher net investment income, fueled this segment’s revenue expansion. Medicaid enrollment was bolstered by winning new contracts, offsetting some redetermination impacts. |
Health Services | -6% | The loss of a large client and pharmacy client price improvements pressured revenues. These headwinds outweighed growth in specialty pharmacy and health care delivery assets, resulting in a net decline compared to the prior year. |
Pharmacy & Consumer Wellness | +12% | Increased prescription volume and a favorable pharmacy drug mix drove sales, partially offset by reimbursement pressures and lower front-store volume. The segment benefited from improved generic purchasing but faced reduced COVID-19-related revenues versus the prior year. |
Operating Income (EBIT) | -77% | The steep decline reflects restructuring charges, acquisition-related costs, and higher medical costs in Health Care Benefits. While the absence of some prior-year litigation charges provided relief, segment-specific margin pressures ultimately drove EBIT down significantly. |
Net Income | -97% | Lower operating income, increased interest expense from debt financing for acquisitions, and higher utilization in Medicare Advantage contributed to the sharp drop. Although certain one-time charges from the prior year did not recur, overall profitability was constrained by these factors. |
| Topic | Previous Mentions | Current Period | Trend |
|---|---|---|---|
Pharmacy & Consumer Wellness | Consistently growing revenues (e.g., $29.8B in Q2 2024, $29B in Q1 2024, over $31B in Q4 2023), with increasing script share around 27%. | Revenue reached $32.4B, up 12% YOY and 15% same-store; prescription share at 27.3%, up 70 bps YOY. | Continues to be a key growth driver; prescription volumes and market share steadily rising. |
Pharmacy Pricing Models | Previously described as central to simplifying drug pricing and mitigating margin pressure (Q2, Q1, Q4 2023). | Cost Vantage and TrueCost both cited as means to address reimbursement pressure. | Ongoing focus; models continue to gain adoption and are intended to reduce cost volatility. |
Health Care Benefits (MA Margins) | Sustained margin pressures in Medicare Advantage across Q2, Q1, Q4 2023, with cost trends and utilization exceeding expectations. | Elevated utilization and a $924M adjusted operating loss, driven by a $1.1B premium deficiency reserve ; slight shift in long-term margin goal to 3–5%. | Sentiment worsening due to higher costs but strategies in place to restore margins. |
Acquisitions (Signify, Oak Street) | Prior mentions highlighted growth and synergy with Aetna, including expanded membership in Q2, Q1, and Q4 2023. | Strong integration with Aetna; Signify revenue up 37% YOY, Oak Street revenue up 36%. | Positive contribution continues; viewed as strategic assets for care delivery expansion. |
Biosimilars & Cordavis | Cordavis cited in prior quarters for driving cost savings through low-priced biosimilars (Q2, Q1, Q4 2023). | Leadership in biosimilar adoption credited with lowering specialty pharmacy trend to 1.3%. | Ongoing expansion; remains a significant cost-reduction lever. |
Use of AI & Automation | Mentioned in Q2 2024 as part of enterprise productivity and in Q1 2024 for improving care management effectiveness; not discussed in Q4 2023. | Highlighted for streamlining care management and detecting utilization patterns. | Increasing emphasis since Q1 2024; supports operational efficiencies and cost savings. |
Regulatory & Legislative Risks | PBM transparency under scrutiny in Q2 and Q4 2023; IRA impacts discussed in Q4 2023 for Medicare Part D. | Brief reference to IRA Part D design changes but no deep PBM transparency detail. | Continues to be monitored; partial updates in current period but no major legislative developments noted. |
Guidance for 2024 & Volatility | Q2 2024 included revised guidance but no outright withdrawal; Q1 and Q4 2023 did not address a complete lack of formal guidance. | No formal EPS guidance given; cited low visibility due to elevated MA costs and reserves. | New caution; uncertain outlook for 2024 amid cost pressures. |
4-5% MA Margin Strategy | Prior statements targeted a 4-5% MA margin over multiple years (Q2, Q1, Q4 2023). | Slightly adjusted to 3-5% long-term, expecting margin recovery via 2025 bids. | Under revision due to cost headwinds; multi-year plan still in progress. |
Insourcing, Large Client Losses, Reserves | Similar references in Q2 and Q1 2024 regarding big client departures and one-time reserve items; no mention in Q4 2023. | Large client loss cited in Health Services; $1.1B in PDR for Medicare and exchange businesses. | Recurring issue, particularly in first three quarters of 2024; contributes to near-term earnings volatility. |
-
Medicare Advantage Margin Outlook
Q: What's the plan to improve MA margins over years?
A: Management aims to improve Medicare Advantage margins but notes that due to changes from the Inflation Reduction Act affecting the Part D program, their target margin range has shifted from 4%–5% down to 3%–5%. They've restructured benefits to drive margin improvement in 2025 and anticipate further gains into 2026, aided by better Star ratings, with two-thirds of members in 4.5-star plans. -
Exchange Business Losses and Actions
Q: What's happening with the exchange business and future plans?
A: The exchange business faced significant losses in 2024, being a $10 billion block with over 1.9 million members. Growth was too fast, especially among SEP members, and they suffered from unfavorable product mix. They've implemented double-digit rate increases and expect to shrink the book by 20%–25% next year to improve performance. -
Potential PDRs and Financial Impacts
Q: Are there PDRs needed for 2025, and what's the impact?
A: Management does not anticipate needing premium deficiency reserves (PDRs) for individual Medicare or exchange businesses in 2025. However, a PDR might be required for the group Medicare business due to multi-year contracts and less flexibility to improve year-over-year. -
Pharmacy Services Outlook
Q: How is the outlook for pharmacy services next year?
A: After a slow start in 2024, the Health Services segment gained momentum in Q2 and Q3. They're entering a strong selling season, with successes in biosimilar launches and high client satisfaction. Management expects continued strong performance but remains cautious given last year's slow start. -
Signify and Oak Street Performance
Q: Are Signify and Oak Street meeting expectations?
A: Signify had a great year with volumes up 37% year-over-year in Q3. Oak Street performed in line with guidance; while facing Medicare market pressures, they've maintained a risk adjustment headwind below 3%. There's potential for positive tailwinds next year as they grow Aetna membership in clinics. -
Cost Vantage Program Progress
Q: What's the status of the Cost Vantage program?
A: The Cost Vantage program, launched to address reimbursement pressures, now has over 50% of clients enrolled. They expect to have 100% of their commercial book signed by year-end. Management is excited about its potential to transform pharmaceutical pricing and reduce cross-subsidization. -
Medicare Advantage Bids and Disenrollment
Q: How are MA bids affecting membership and margins?
A: Early indicators suggest membership will decline by 5%–10%, mainly in individual and dual-eligible populations. They've made deliberate benefit design changes and exited underperforming areas, impacting nearly 0.5 million members, to improve profitability in 2025. An $800 million tailwind is expected from contracts now rated 4 stars or better.